CALA News and Press, Calithera Biosciences Inc. From 01/15/21

Gainers: ObsEva (OBSV) +56%, DBV Technologies (DBVT) +44%, Senseonics Holdings (SENS) +39%, Avinger (AVGR) +33%, Bionano Genomics (BNGO) +28%.Losers: Cardiff Oncology (CRDF) -20%, SOS (SOS) -18%, Lexicon Pharmaceuticals (LXRX) -11%,&...

SOUTH SAN FRANCISCO, Calif., Jan. 11, 2021 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage biotechnology company focused on discovering and developing novel small molecule drugs for the treatment of cancer and other life-threatening diseases, today announced...

Listen on the go! A daily podcast of Wall Street Breakfast will be available by 8:00 a.m. on Seeking Alpha, iTunes, Stitcher and Spotify. The three major U.S. stock averages ended Friday at all-time highs despite a weak December jobs report, in a session that zigzagged with the hopes of furth...

SOUTH SAN FRANCISCO, Calif., Jan. 05, 2021 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage biotechnology company focused on discovering and developing novel small molecule drugs for the treatment of cancer and other life-threatening diseases, today announced...

Gainers: Check-Cap (CHEK) +185%.Bionano Genomics (BNGO) +99%.The9 (NCTY) +92%.Ocugen (OCGN) +74%.Jaguar Health (JAGX) +42%.Pandion Therapeutics (PAND) +37%.ViewRay (VRAY) +33%.Bit Digital (BTBT) +29%.AirNet Technology (ANTE) +18%.Studio City International (MSC) +18%.Losers: ...

Calithera Biosciences (NASDAQ: CALA) , a clinical-stage biotech company, reported on Monday morning that telaglenastat, one of its leading pipeline candidates, flopped in a clinical trial. As a result, investors are selling-off shares of the company. As of 11:53 a.m. EST on Monday, ...

Calithera Biosciences (CALA) -56% as telaglenastat fails in kidney cancer study; lowers headcount.Genworth Financial (GNW) -29% after merger end-date passes.QuantumScape (QS) -18%.AeroCentury (ACY) -12%.FG Financial Group (FGF) -11%.Chindata Group Holdings (CD) -10%.PEDEVC...

Calithera Biosciences (CALA) plunges 35% in premarket in reaction to topline results from the CANTATA Phase 2 study evaluating its glutaminase inhibitor telaglenastat in combination with cabozantinib, in patients with advanced or metastatic renal cell carcinoma.The study failed to&#...

-- Company will continue to advance telaglenastat KEAPSAKE trial in non-small cell lung cancer, arginase inhibitor CB-280 trial in cystic fibrosis and emerging pipeline -- Company to host webcast and conference call today at 8:30 a.m. ET / 5:30 a.m. PT SOUTH SAN FRANCISCO, Calif.,...

Calithera has an important near-term catalyst that could launch the company into a significant commercialization opportunity by mid-year 2021. The company also is running a triplet therapy trial that if successful, would be the only treatment in a $10B market. Calithera is a high-...